Raisa S. Abrams-Pompe

Dr. Raisa S. Abrams-Pompe


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AKAndra Kuske
Andra Kuske
TGTobias M. Gorges
Tobias M. Gorges
PTPierre Tennstedt
Pierre Tennstedt
ATAnne-Kathrin Tiebel
Anne-Kathrin Tiebel
RARaisa S. Abrams-Pompe
Raisa S. Abrams-Pompe
KPKlaus Pantel
Klaus Pantel
The relevance of blood-based assays to monitor minimal residual disease (MRD) in non-metastatic prostate cancer (PCa) remains unclear. Proving that clinically relevant circulating tumor cells (CTCs) can be detected with available technologies could address this. This study aimed to improve CTC detection in non-metastatic PCa patients by combining three independent CTC assays: the CellSearch system, an in vivo CellCollector and the EPISPOT. Peripheral blood samples from high-risk PCa patients were screened for CTCs before and three months after radical prostatectomy (RP). Combining the results of both time points, CTCs were detected in 37%, 54.9% and 58.7% of patients using CellSearch, CellCollector and EPISPOT, respectively. The cumulative positivity rate of the three CTC assays was 81.3% (87/107) with 21.5% (23/107) of patients harboring ≥5 CTCs/7.5 ml blood. Matched pair analysis of 30 blood samples taken before and after surgery indicated a significant decrease in CTCs captured by the CellCollector from 66% before RP to 34% after therapy (p = 0.031). CTC detection by EPISPOT before RP significantly correlated with PSA serum values (p < 0.0001) and clinical tumor stage (p = 0.04), while the other assays showed no significant correlations. In conclusion, CTC-based liquid biopsies have the potential to monitor MRD in patients with non-metastatic prostate cancer.

1 October 2017 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
EZEmanuele Zaffuto
Emanuele Zaffuto
RARaisa S. Abrams-Pompe
Raisa S. Abrams-Pompe
MZMarc Zanaty
Marc Zanaty
HBHelen Davis Bondarenko
Helen Davis Bondarenko
SLSami-Ramzi Leyh-Bannurah
Sami-Ramzi Leyh-Bannurah
PKPierre I. Karakiewicz
Pierre I. Karakiewicz

1 March 2017 in European Urology
Verified
Journal Article
Closed access
MAMeike Adam
Meike Adam
PTPierre Tennstedt
Pierre Tennstedt
DLDominik Lanwehr
Dominik Lanwehr
DTDerya Tilki
Derya Tilki
TSThomas Steuber
Thomas Steuber
TSThorsten Schlomm
Thorsten Schlomm

1 November 2015 in European Journal of Cancer
Verified
Journal Article
Closed access
RARaisa S. Abrams-Pompe
Raisa S. Abrams-Pompe
ABAndré O. von Bueren
André O. von Bueren
MMMartin Mynarek
Martin Mynarek
KHKatja von Hoff
Katja von Hoff
CFCarsten Friedrich
Carsten Friedrich
SRStefan Rutkowski
Stefan Rutkowski

19 February 2018 in The Prostate
Verified
Journal Article
Closed access
PDF file
FPFelix Preisser
Felix Preisser
MBMarco Bandini
Marco Bandini
MMMichele Marchioni
Michele Marchioni
SNSebastiano Nazzani
Sebastiano Nazzani
ZTZhe Tian
Zhe Tian
PKPierre I. Karakiewicz
Pierre I. Karakiewicz

1 August 2017 in Journal of Urology
Verified
Journal Article
Closed access
RARaisa S. Abrams-Pompe
Raisa S. Abrams-Pompe
PKPierre I. Karakiewicz
Pierre I. Karakiewicz
ZTZhe Tian
Zhe Tian
PMPhilipp Mandel
Philipp Mandel
TSThomas Steuber
Thomas Steuber
DTDerya Tilki
Derya Tilki
We validated the current NCCN (National Comprehensive Cancer Network®) classification of very high risk patients, and compared the pathological, functional and oncologic outcomes between surgically treated high risk and very high risk patients. We retrospectively analyzed 4,041 patients stratified into high risk or very high risk groups who underwent radical prostatectomy between 1992 and 2016. Kaplan-Meier as well as multivariable logistic and Cox regression analyses were used to compare outcomes between the groups. After radical prostatectomy the rate of adverse pathological features was higher in 1,369 very high risk vs 2,672 high risk cases. Functional outcomes were similar between the groups, with 1-year continence and potency rates of 81.0% and 43.6% in the very high risk compared to 81.9% and 45.2% in the high risk group, respectively (p = 0.7 and p = 0.9). In a subset of 1,835 patients who underwent radical prostatectomy between 1992 and 2011 (median followup 58.8 months, IQR 36.5-84.6), those with very high risk disease had significantly worse 5 and 8-year biochemical recurrence-free survival, metastatic progression-free survival, prostate cancer specific mortality-free survival and overall survival rates compared to those with high risk disease. Despite the relatively poor prognosis of patients with high risk prostate cancer, radical prostatectomy results in favorable 5 and 8-year metastatic progression-free survival, prostate cancer specific mortality-free survival and overall survival rates. Relative to high risk cases, their very high risk counterparts have significantly worse pathological and oncologic outcomes, and more frequently require additional therapies. These observations validate the stratification between high risk and very high risk in European patients with prostate cancer. Interestingly, very high risk patients treated with radical prostatectomy did not have a worse functional outcome than their high risk counterparts.